icon-    folder.gif   Conference Reports for NATAP  
 
  IAS 2015: 8th IAS Conference on
HIV Pathogenesis Treatment and Prevention
Vancouver, Canada
18-22 July 2015
Back grey_arrow_rt.gif
 
 
 
HCV/HIV Coinfection at IAS Vancouver 2015 July 19-23
 
 
  IAS: C-EDGE CO-INFECTED: Phase 3 Study of Grazoprevir / Elbasvir in Patients with HCV/HIV - (07/22/15)
 
IAS: Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1 - (07/24/15)
 
IAS: Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1 - (07/24/15)
 
IAS: More Diabetes and CVD, Shorter Survival, in HIV/HCV-Positives With Steatosis (07/22/15)
 
IAS: Abbvie 3D in HCV/HIV Update ......HIGH SVR RATES IN HCV/HIV-1 CO-INFECTED PATIENTS REGARDLESS OF BASELINE CHARACTERISTICS........(note IDUs had 100% SVR) - (07/22/15)
 
IAS: DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HIV-HCV COINFECTION: INTERIM ANALYSIS OF A FRENCH MULTICENTER COMPASSIONATE USE PROGRAM (AI444-258) - (07/22/15)
 
IAS: Ledipasvir/sofosbuvir for 12 Weeks in Patients Coinfected With HCV and hiv-1: ION-4 - (07/22/15)
 
IAS: Frequent Fibrosis Regression With SVR in HCV/HIV+, Cutting Death Risk - (07/28/15)

Overall.gif